ACE and Renal insufficiency: Features of patient populations at-risk for DRVs have been consistently described (the elderly, those with impaired cognition, dependent living situations, renal insufficiency, multiple comorbidities or polypharmacy) as have the most common offending therapies (antiplatelets, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDS), diuretics, angiotensin converting enzyme (ACE) inhibitors, opioids, and diabetes treatments) [6]–[8].